Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
CC-115 · 1 trial · 6 indications
| Arm | Type | Description |
|---|---|---|
| CC-115 | EXPERIMENTAL | - |
| Name | Type | Description |
|---|---|---|
| CC-115 | DRUG | Part A (actively recruiting): Dose level starts with 0.5mg daily by mouth in cycles of 28 days. Level increases for different patient cohorts in 100% or 50% increments until optimal dose schedule is established for further study. Treatment continues for as long as patient benefits (i.e., until disease progression or unacceptable toxicity). Part B: Optimal dose schedule is administered in 28-day cycles until disease progression. |
Inclusion Criteria: * Histologically-confirmed advanced solid tumor, chronic lymphocytic leukemia, small lymphocytic lymphoma, T-cell prolymphocytic leukemia, Non-Hodgkin Lymphoma or multiple myeloma * Progressed or not tolerated standard therapy, and no further standard therapy is available * Arch...
CC-115 is an investigational small molecule developed by Bristol-Myers Squibb Company (NYSE: BMY). It is being studied in oncology, including glioblastoma multiforme, and is in Phase 1 clinical development. CC-115 has not been approved by the FDA and remains an investigational agent.
CC-115 is being studied for the treatment of glioblastoma multiforme, a type of brain cancer, along with other advanced solid tumors and hematologic malignancies. It is an investigational therapy in Phase 1 development and is not approved for any indication.
CC-115 targets PRKDC and MTOR. It is an inhibitor of both targets, meaning it is designed to block the activity of these proteins. This dual-target profile is the basis for its study in advanced solid tumors and hematologic malignancies.
CC-115 is developed by Bristol-Myers Squibb Company, which trades on the New York Stock Exchange under the ticker BMY. The company is the sponsor of the clinical program evaluating CC-115 in oncology.
CC-115 is in Phase 1 clinical development. It is an investigational drug and has not been approved by the FDA. The Phase 1 program has completed, with one trial conducted and no active trials currently listed.
CC-115 has been evaluated in one completed Phase 1 trial, NCT01353625, titled a study to assess safety and tolerability of oral CC-115 for patients with advanced solid tumors and hematologic malignancies. The trial enrolled 118 patients across the United States, France, Germany, and Spain.